TSX:FTS

Newfoundland Power and Mysa Launch takeCHARGE Smart Thermostat Pilot: How NL Households Can Earn Up to $140 for Cutting Peak Demand

Newfoundland Power and Mysa have launched a winter pilot offering up to $140 in rewards to households that reduce electricity use during peak demand. The program uses smart thermostats to make small, temporary heating adjustments, which participants can override. The initiative comes as Island system demand hit 1,230 MW on Dec. 15, with utilities seeking ways to ease winter grid strain.

16 December 2025

Home Improvement·NYSE:FTS·Smart Home·TSX:FTS

B.C. Storm Power Outages: Thousands Lose Electricity in Greater Victoria, Fort St. John and Kaslo – Latest Updates for December 6, 2025

High winds and heavy rain knocked out power to over 9,000 customers across British Columbia on Friday, with major outages in Fort St. John, Kaslo, and Vancouver Island’s West Shore. Service was restored in Fort St. John and Kaslo by Saturday, but BC Hydro crews continued repairs in Metchosin, Royal Bay, and South Langford after a tree downed lines.

6 December 2025

TSX:FTS·Weather

Fortis Inc. (TSX: FTS) Stock on December 3, 2025: Latest News, Dividend Hike and 2026 Analyst Forecast

Fortis Inc. shares traded near C$72.27 on the TSX December 3, 2025, after breaking above their 200-day moving average of C$68.55. The company announced a 4% dividend increase, a new C$28.8 billion capital plan, and completed the sale of Caribbean assets. Market capitalization stands near US$25.9 billion. Large investors including HSBC and 1832 Asset Management disclosed modest position reductions.

3 December 2025

Dividends·NYSE:FTS·Stock Market·TSX:FTS

Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).